Alzheimer’s disease could be detectable in middle age, leading to subtle memory issues, according to recent research findings. The Lancet study investigated the potential of a blood test to identify the most prevalent form of dementia and diagnose individuals many years before visible symptoms manifest.
The research conducted by US scientists involved analyzing blood samples from 1,350 individuals without dementia, focusing on biomarkers associated with the accumulation of amyloid and tau proteins in the brain, a hallmark of Alzheimer’s. Participants, with an average age of 61, who exhibited high levels of these biomarkers also displayed lower performance on tests assessing verbal memory and cognitive speed.
Professor Kristine Yaffe from the University of California suggested that utilizing blood tests could aid in targeting preventive measures and clinical trials aimed at delaying or preventing dementia onset. The study emphasized that Alzheimer’s disease may initiate decades before noticeable symptoms appear, underscoring the potential of plasma biomarkers for early detection in the general populace.
While it remains uncertain whether individuals with amyloid and tau biomarkers will progress to develop Alzheimer’s, ongoing research seeks to comprehend the role of these proteins in disease development. Efforts are underway to develop an effective blood test for early dementia diagnosis to mitigate cognitive decline. The NHS is actively recruiting participants for a £10 million clinical trial known as the ‘Blood Biomarker Challenge’ project, supported by the People’s Postcode Lottery.
In parallel, clinical trials are investigating drugs that could potentially halt the advancement of the disease, albeit requiring administration during the initial stages of Alzheimer’s. Another study published in the Lancet introduced a novel approach for early detection of tau protein tangles through advanced brain imaging techniques, comparing the efficacy of different tracers.
Dr. Jacqui Hanley from Alzheimer’s Research UK noted that these studies contribute to the growing body of evidence indicating progress in detecting biological changes linked to Alzheimer’s disease at earlier stages. Early identification of these changes could offer valuable opportunities for participation in new treatment studies and access to disease-modifying treatments suitable for early-stage conditions.
With an estimated one million Britons currently affected by dementia, a figure projected to rise to 1.4 million by 2040, the urgency to enhance diagnostic approaches and treatment options for Alzheimer’s is paramount. Professor Paresh Malhotra from Imperial College London highlighted the significance of the recent blood tests and their potential impact on identifying abnormal Alzheimer’s biomarkers in individuals before cognitive symptoms become prevalent.
